<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03877952</url>
  </required_header>
  <id_info>
    <org_study_id>CORT125281-602</org_study_id>
    <secondary_id>2018-001700-11</secondary_id>
    <nct_id>NCT03877952</nct_id>
  </id_info>
  <brief_title>Mass Balance Recovery and Metabolite Profile of CORT125281 in Healthy Male Participants</brief_title>
  <official_title>A Phase 1 Open-label, Single-dose Study Designed to Assess the Mass Balance Recovery and Metabolite Profile and to Identify Metabolite Structures for [14C]-CORT125281 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Corcept Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Corcept Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the mass balance recovery and metabolite profile, and will identify
      metabolite structures following a single oral dose of 14C-CORT125281 in healthy participants.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 13, 2018</start_date>
  <completion_date type="Actual">November 2, 2018</completion_date>
  <primary_completion_date type="Actual">November 1, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mass Balance Recovery in Excreta After a Single Oral Dose of 14C-CORT125281</measure>
    <time_frame>Until the mass balance criteria for all participants have been met (estimated up to 10 days)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mass Balance Recovery in Urine After a Single Oral Dose of 14C-CORT125281</measure>
    <time_frame>Until the mass balance criteria for all participants have been met (estimated up to 10 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mass Balance Recovery in Feces After a Single Oral Dose of 14C-CORT125281</measure>
    <time_frame>Until the mass balance criteria for all participants have been met (estimated up to 10 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Pharmacokinetics (PK) of Total Radioactivity after Oral Dosing: Peak Plasma Concentration (Cmax)</measure>
    <time_frame>Pre-dose and at pre-specified time points up to Day 8 after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma PK of Total Radioactivity after Oral Dosing: Time from Dosing to Cmax (tmax)</measure>
    <time_frame>Pre-dose and at pre-specified time points up to Day 8 after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma PK of Total Radioactivity after Oral Dosing: Area Under the Plasma Concentration-time Curve from Zero Time to Time of the Last Measurable Concentration (AUC0-last)</measure>
    <time_frame>Pre-dose and at pre-specified time points up to Day 8 after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma PK of Total Radioactivity after Oral Dosing: Apparent Elimination Half-life (t1/2)</measure>
    <time_frame>Pre-dose and at pre-specified time points up to Day 8 after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma PK of Total Radioactivity after Oral Dosing: Mean Residence Time (MRT)</measure>
    <time_frame>Pre-dose and at pre-specified time points up to Day 8 after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma PK of CORT125281 after Oral Dosing: Cmax</measure>
    <time_frame>Pre-dose and at pre-specified time points up to Day 8 after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma PK of CORT125281 after Oral Dosing: tmax</measure>
    <time_frame>Pre-dose and at pre-specified time points up to Day 8 after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma PK of CORT125281 after Oral Dosing: AUC0-last</measure>
    <time_frame>Pre-dose and at pre-specified time points up to Day 8 after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma PK of CORT125281 after Oral Dosing: t1/2</measure>
    <time_frame>Pre-dose and at pre-specified time points up to Day 8 after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma PK of CORT125281 after Oral Dosing: MRT</measure>
    <time_frame>Pre-dose and at pre-specified time points up to Day 8 after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of Total Radioactivity into Red Blood Cells after Oral Dosing</measure>
    <time_frame>Pre-dose and at pre-specified time points up to Day 8 after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of CORT125281 Metabolites Accounting for ≥10% of Total Radioactivity Detected in Plasma, Urine, and Feces</measure>
    <time_frame>Until the mass balance criteria for all participants have been met (estimated up to 10 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with One or More Adverse Events</measure>
    <time_frame>Until the mass balance criteria for all participants have been met (estimated up to 10 days)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Study Participants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>On Day 1, participants will receive a single oral dose of 14C-CORT125281 360 mg (6 X 60 mg capsules) after an overnight fast.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>14C-CORT125281</intervention_name>
    <description>14C-CORT125281 360 mg capsule for oral administration containing not more than 2.5 megaBequerel (67 μCi) 14C</description>
    <arm_group_label>Study Participants</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body mass index 18.0 to 30.0 kg/m^2, inclusive

          -  Provide written informed consent

          -  Have regular bowel movements (i.e., average stool production of ≥1 and ≤3 stools per
             day)

          -  Able to swallow capsules

          -  Adhere to specified contraception requirements.

        Exclusion Criteria:

          -  Have received any investigational medicine in a clinical research study within the
             previous 3 months, or CORT125281 at any time

          -  Have a pregnant partner

          -  Employees or immediate family members of employees of the study site or Sponsor

          -  History of abuse of any drug or alcohol, or regularly consume more than 21 units
             alcohol/week

          -  Smokers or users of e-cigarettes and nicotine replacement products within the last 6
             months

          -  Occupationally exposed worker, as defined in the Ionising Radiation Regulations 2017;
             greater than background radiation exposure from other sources exceeding 5
             milliSieverts (mSv) in the last 12 months or 10 mSv in the last 5 years

          -  Clinically significant abnormal results of clinical laboratory safety tests,
             electrocardiogram, or measurement of heart rate and blood pressure

          -  History of clinically significant cardiovascular, renal, hepatic, respiratory or
             gastrointestinal disease, neurological or psychiatric disorder

          -  History and/or symptoms of adrenal insufficiency or any condition that could be
             aggravated by glucocorticoid blockade (e.g., an autoimmune disease; allergy requiring
             treatment)

          -  Donation or loss of greater than 400 mL of blood within the previous 3 months

          -  Are taking, or have taken, any prescribed or over-the-counter drug or vitamins/herbal
             remedies within 1 week (longer restrictions apply for some medicines).

        NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sharan Sidhu, MBChB, BAO, MRCS, MFPM</last_name>
    <role>Principal Investigator</role>
    <affiliation>Quotient Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Quotient Sciences</name>
      <address>
        <city>Ruddington</city>
        <state>Nottingham</state>
        <zip>NG11 6JS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 14, 2019</study_first_submitted>
  <study_first_submitted_qc>March 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 18, 2019</study_first_posted>
  <last_update_submitted>March 14, 2019</last_update_submitted>
  <last_update_submitted_qc>March 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

